drugset / Trial / NCT04684446
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
Phase 1/2
Completed
100 enrolled
R-Pharm
AstraZeneca · collabRussian Direct Investment Fund · collabThe Gamaleya National Center of Epidemiology & Microbiology · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2021-11-26
- Completion
- 2022-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1222 | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | rAd26-S | Vaccine | 1e+11 unknown | Intramuscular |